Unbound Cloxacillin Concentrations During Continuous Infusion

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorEmeli Månsson

About this trial

Cloxacillin is the first-line choice for the treatment of severe infections caused by the bacterium Staphylococcus aureus in Sweden. Over the past year, cloxacillin is increasingly administred through continuous infusion. In this study, the free (unbound) concentration of cloxacillin when administered as a continuous infusion will be measured to ensure that the free concentration is neither too high nor too low. A PK/PD model will be developed to predict which dosage of cloxacillin is appropriate for an individual based on age, gender, kidney function, and serum-protein level.

Eligibility criteria

Qualifiers

Age 18 years or older

Treating physician has decided to start continuous infusion of cloxacillin

Disqualifiers

Unwilling or unable to provide written informed consent

Trial design

Treatments tested in this trial

  • Unbound cloxacillin concentration

Treatment groups

25 Participants
are divided into 1 treatment group

Sponsors and collaborators

Emeli Månsson

Lead sponsor

Region Västmanland

Sponsor institution

Region Västmanland

Collaborator